Biogen Reports First Quarter 2016 Revenues of $2.7 Billion

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) today reported first quarter 2016 financial results, including:

• Total revenues of $2.7 billion, a 7% increase versus the same period in the prior year. Growth was driven by a 15% increase in worldwide TECFIDERA® revenues as well as increased revenues from ELOCTATE® and ALPROLIX®.

Revenues were partially offset by a decrease in worldwide interferon sales. ? Foreign exchange, including a $26 million reduction in hedging gains, negatively impacted total revenues by approximately $50 million compared to the first quarter of 2015.

MORE ON THIS TOPIC